Drug intelligence / Profile preview

Wuhan Univ. hexokinase 1 (HK1) compound 34b

Development stage: Unknown
Lead developer: Wuhan University

Overview

Wuhan Univ. hexokinase 1 (HK1) compound 34b: sourced facts only. name: "Moreover, hexokinase 1 (HK1) was identified as a direct target of 34b." [PMID:35611405]; target: "Moreover, hexokinase 1 (HK1) was identified as a direct target of 34b." [PMID:35611405]; developer: "College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China." [PMID:35611405]; stage: "In vivo, 34b had a favorable pharmacokinetic profile with a bioavailability of 23.20% and exhibited more potent tumor suppression than tamoxifen both in MCF-7 and LCC2 tumor xenograft models." [PMID:35611405]

Targets

HK1 (Hexokinase type I (mitochondrial))

Beyond the preview

Go deeper on Wuhan Univ. hexokinase 1 (HK1) compound 34b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Univ. hexokinase 1 (HK1) compound 34b.